

☐ Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>WARBURG PINCUS LLC</u>  (Last) (First) (Middle) <u>C/O WARBURG PINCUS LLC</u> <u>450 LEXINGTON AVEUE</u>  (Street) <u>NEW YORK</u> <u>NY</u> <u>10017</u>  (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>Alignment Healthcare, Inc.</u> [ <u>ALHC</u> ]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  <input checked="" type="checkbox"/> Director <input checked="" type="checkbox"/> 10% Owner  Officer (give title below) Other (specify below)
	3. Date of Earliest Transaction (Month/Day/Year) <u>03/30/2021</u>	
	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line)  <input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock, par value \$0.001 per share	03/30/2021		S <sup>(1)</sup>		1,251,670	D	\$16.83	25,519,345	I	See footnote <sup>(2)(3)</sup>

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				

1. Name and Address of Reporting Person* <u>WARBURG PINCUS LLC</u>  (Last) (First) (Middle) <u>C/O WARBURG PINCUS LLC</u> <u>450 LEXINGTON AVEUE</u>  (Street) <u>NEW YORK</u> <u>NY</u> <u>10017</u>  (City) (State) (Zip)
1. Name and Address of Reporting Person* <u>Warburg Pincus Private Equity XII, L.P.</u>  (Last) (First) (Middle) <u>C/O WARBURG PINCUS LLC</u> <u>450 LEXINTON AVENUE</u>  (Street) <u>NEW YORK</u> <u>NY</u> <u>10017</u>  (City) (State) (Zip)
1. Name and Address of Reporting Person* <u>Warburg Pincus Private Equity XII-B, L.P.</u>  (Last) (First) (Middle) <u>C/O WARBURG PINCUS</u>

450 LEXINGTON AVENUE

(Street)  
NEW YORK NY 10017

(City) (State) (Zip)

1. Name and Address of Reporting Person\*  
[Warburg Pincus Private Equity XII-D, L.P.](#)

(Last) (First) (Middle)  
C/O WARBURG PINCUS  
450 LEXINGTON AVENUE

(Street)  
NEW YORK NY 10017

(City) (State) (Zip)

1. Name and Address of Reporting Person\*  
[Warburg Pincus Private Equity XII-E, L.P.](#)

(Last) (First) (Middle)  
C/O WARBURG PINCUS  
450 LEXINGTON AVENUE

(Street)  
NEW YORK NY 10017

(City) (State) (Zip)

1. Name and Address of Reporting Person\*  
[WP XII Partners, L.P.](#)

(Last) (First) (Middle)  
C/O WARBURG PINCUS, LLC.  
450 LEXINGTON AVENUE

(Street)  
NEW YORK NY 10017

(City) (State) (Zip)

1. Name and Address of Reporting Person\*  
[Warburg Pincus XII Partners, L.P.](#)

(Last) (First) (Middle)  
C/O WARBURG PINCUS LLC  
450 LEXINGTON AVENUE

(Street)  
NEW YORK NY 10017

(City) (State) (Zip)

1. Name and Address of Reporting Person\*  
[WARBURG PINCUS XII, L.P.](#)

(Last) (First) (Middle)  
C/O WARBURG PINCUS LLC  
450 LEXINGTON AVENUE

(Street)  
NEW YORK NY 10017

(City) (State) (Zip)

1. Name and Address of Reporting Person\*  
[WP Global LLC](#)

(Last) (First) (Middle)

C/O WARBURG PINCUS LLC		
55 EAST 52ND STREET, 33RD FLOOR		
(Street)		
NEW YORK	NY	10017
(City)	(State)	(Zip)

1. Name and Address of Reporting Person\*

Warburg Pincus Partners II, L.P.

(Last)

(First)

(Middle)

C/O WARBURG PINCUS LLC

450 LEXINGTON AVENUE

(Street)

NEW YORK

NY

10017

(City)

(State)

(Zip)

Explanation of Responses:

1. Represents 806,213 shares of Common Stock sold by Warburg Pincus Private Equity XII, L.P., a Delaware limited partnership ("WP XII"), 161,753 shares of Common Stock sold by Warburg Pincus Private Equity XII-B, L.P., a Delaware limited partnership ("WP XII-B"), 23,269 shares of Common Stock sold by Warburg Pincus Private Equity XII-D, L.P., a Delaware limited partnership ("WP XII-D"), and 132,802 share of Common Stock sold by Warburg Pincus Private Equity XII-E, L.P., a Delaware limited partnership ("WP XII-E"), 43,496 shares of Common Stock sold by WP XII Partners, L.P., a Delaware limited partnership ("WP XII Partners"), 84,137 shares of Common Stock sold by Warburg Pincus XII Partners, L.P., a Delaware limited partnership ("Warburg Pincus XII Partners") in the initial public offering of Alignment Healthcare, Inc. which closed on March 30, 2021 (the "Offering"), at a price of \$16.83 (net of underwriting discount).

2. Reflects securities held directly by WP XII, WP XII-B, WP XII-D, WP XII-E, WP XII Partners, and Warburg Pincus XII Partners (together with WP XII, WP XII-B, WP XII-D, WP XII-E, and WP XII Partners, the "WP XII Funds") following the closing of the Offering. Warburg Pincus XII, L.P., a Delaware limited partnership ("WP XII GP"), is the general partner of the WP XII Funds. WP Global LLC, a Delaware limited liability company ("WP Global"), is the general partner of WP XII GP. Warburg Pincus Partners II, L.P., a Delaware limited partnership ("WPP II"), is the managing member of WP Global. Warburg Pincus Partners GP LLC, a Delaware limited liability company ("WPP GP"), is the general partner of WPP II. Warburg Pincus & Co., a New York general partnership ("WP"), is the managing member of WPP GP. Warburg Pincus LLC, a New York limited liability company ("WP LLC") is a registered investment adviser and the manager of the WP XII Funds.

3. (Continued from footnote 2) Investment and voting decisions with respect to the shares held by the WP XII Funds are made by a committee comprised of three or more individuals and all members of such committee disclaim beneficial ownership of the shares.

Remarks:

WP XII, WP XII-B, WP XII-D, WP XII-E, WP XII Partners, Warburg Pincus XII Partners, WP XII GP, WP Global, WPP II, WPP GP, and WP may be deemed to be members of a "group" for the purposes of the Securities Exchange Act of 1934. Each reporting person disclaims beneficial ownership of any securities deemed to be owned by the group that are not directly owned by the reporting person. This report shall not be deemed an admission that the reporting persons are a member of a group or the beneficial owner of any securities not directly owned by the reporting person. Each of the reporting persons is a director-by-deputization solely for purposes of Section 16 of the Exchange Act. Form 1 of 2.

[Warburg Pincus LLC, By: /s/ Harsha Marti, General Counsel & Managing Director](#)  
[Warburg Pincus Private Equity XII, L.P., By: Warburg Pincus XII, L.P., By: WP Global LLC, By: Warburg Pincus Partners II, L.P., By: Warburg Pincus Partners GP LLC, By: Warburg Pincus & Co., By: /s/ Harsha Marti, Partner](#)  
[Warburg Pincus Private Equity XII-B, L.P., By: Warburg Pincus XII, L.P., By: WP Global LLC, By: Warburg Pincus Partners II, L.P., By: Warburg Pincus Partners GP LLC, By: Warburg Pincus & Co., By: /s/ Harsha Marti, Partner](#)  
[Warburg Pincus Private Equity XII-D, L.P., By: Warburg Pincus XII, L.P., By: WP Global LLC, By: Warburg Pincus Partners II, L.P., By: Warburg Pincus Partners GP LLC, By: Warburg Pincus & Co., By: /s/ Harsha Marti, Partner](#)  
[Warburg Pincus Private Equity XII-E, L.P., By: Warburg Pincus XII, L.P., By: WP Global LLC, By: Warburg Pincus Partners II, L.P., By: Warburg Pincus Partners GP LLC, By: Warburg Pincus & Co., By: /s/ Harsha Marti, Partner](#)  
[WP XII Partners, L.P., By: Warburg Pincus XII, L.P., By:](#)

[WP Global LLC, By: Warburg Pincus Partners II, L.P., By: Warburg Pincus Partners GP LLC, By: Warburg Pincus & Co., By: /s/ Harsha Marti, Partner](#)  
[Warburg Pincus XII Partners, L.P., By: Warburg Pincus XII, L.P., By: WP Global LLC, By: Warburg Pincus Partners II, L.P., By: Warburg Pincus Partners GP LLC, By: Warburg Pincus & Co., By: /s/ Harsha Marti, Partner](#) [04/01/2021](#)  
[Warburg Pincus XII, L.P., By: Warburg Pincus XII, L.P., By: Warburg Pincus Partners II, L.P., By: Warburg Pincus Partners GP LLC, By: Warburg Pincus Partners GP LLC, WP Global LLC, By: Warburg Pincus Partners II, L.P., By: Warburg Pincus Partners GP LLC, By: Warburg Pincus & Co., By: /s/ Harsha Marti, Partner](#) [04/01/2021](#)  
[WP Global LLC, By: Warburg Pincus Partners II, L.P., By: Warburg Pincus Partners GP LLC, By: Warburg Pincus & Co., By: /s/ Harsha Marti, Partner](#) [04/01/2021](#)  
[Warburg Pincus Partners II, L.P., By: Warburg Pincus Partners GP LLC, By: Warburg Pincus & Co., By: /s/ Harsha Marti, Partner](#) [04/01/2021](#)

\*\* Signature of Reporting Person      Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**